Vineet Laborator (VINEETLAB)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Price-to-book of 1.20 against book value of ₹34.64 is not an excessive premium to stated book.
• Latest quarter shows a small net profit of ₹1 Cr on sales of ₹16 Cr, a possible early positive inflection.
• Profit growth of 114.89% indicates improvement over a very low or negative base.
• Piotroski F-Score of 5/9 is moderate, not deeply distressed.

Concerns

• Promoter holding of just 5.98% is extremely low and raises serious corporate-governance and alignment concerns.
• ROE of -32.96% and ROCE of -27.95% show significant shareholder wealth destruction.
• Debt-to-equity of 3.01 is very high, leaving little room for error.
• Sales declined 13.54% and there is no dividend, so shareholders are getting no income or topline momentum.

AI Analysis

At ₹41.45, Vineet Laborator is a ₹57 Cr micro-cap with a book value of ₹34.64 per share, so the price is 1.20 times book. In ordinary circumstances that looks reasonable, but Graham taught us to look through the balance sheet to earning power. Here earning power is missing: ROE is -32.96% and ROCE is -27.95%. The company is destroying capital. Sales have fallen by 13.54%, and debt-to-equity stands at 3.01, a stretched balance sheet for a small pharmaceutical business. There is no dividend; the P/E is meaningless because annual earnings are near zero. The one fresh sign of life is the latest quarter: sales of ₹16 Cr and net profit of ₹1 Cr. Profit growth of 114.89% sounds eye-catching, but it comes off a very low or negative base. One profitable quarter is not proof of a durable turnaround. Piotroski F-Score of 5/9 is only mediocre, not a sign of strong financial improvement. The biggest warning is promoter holding of just 5.98%. When the people controlling a business own less than six percent, the alignment with minority shareholders is poor. That alone would make me very cautious. The 52-week range from ₹27.96 to ₹49.99 tells me this is a volatile, speculative micro-cap, not a stable compounding machine. Would I invest my own money? No. The price may look close to book, but book value is not sacred while losses and leverage persist. A true margin of safety requires a sound balance sheet, improving returns, and honest ownership. Vineet Laborator does not yet meet that test. I would put it on a watch list and wait for evidence of sustained profitability, debt reduction, and rising capital efficiency. Until then, this is a possible turnaround and an asset-like speculation, not a business I can study with confidence.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer